Atea Pharmaceuticals (AVIR) Aperçu de l'action
Atea Pharmaceuticals, Inc. est une société biopharmaceutique au stade clinique qui découvre, développe et commercialise des thérapies antivirales orales pour les patients souffrant d'infections virales graves. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
AVIR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Atea Pharmaceuticals, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$4.99 |
| Plus haut sur 52 semaines | US$6.45 |
| Plus bas sur 52 semaines | US$2.78 |
| Bêta | 0.32 |
| Variation sur 1 mois | 13.67% |
| Variation sur 3 mois | -11.99% |
| Variation sur 1 an | 35.97% |
| Variation sur 3 ans | 37.09% |
| Variation sur 5 ans | -78.21% |
| Évolution depuis l'introduction en bourse | -83.55% |
Nouvelles et mises à jour récentes
AVIR: Hepatitis Antiviral Pipeline Progress Will Drive A More Optimistic Outlook
The analyst price target for Atea Pharmaceuticals has moved by about $1.00, with analysts pointing to revised fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as the main drivers of this update. What's in the News Atea Pharmaceuticals reported Phase 1 results indicating its fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C had a low risk of drug drug interactions, including with commonly used medications such as omeprazole and rosuvastatin.Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Summary Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR’s BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR’s $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie. Failure in both Phase 3 studies threatens AVIR’s survival, while success could trigger a share price spike or potential acquisition interest. Read the full article on Seeking Alpha
Hepatitis C Trial And Pricing Risks Will Dominate Outlook Yet Longer Term Potential Remains
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral antiviral therapies for hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...Recent updates
AVIR: Hepatitis Antiviral Pipeline Progress Will Drive A More Optimistic Outlook
The analyst price target for Atea Pharmaceuticals has moved by about $1.00, with analysts pointing to revised fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as the main drivers of this update. What's in the News Atea Pharmaceuticals reported Phase 1 results indicating its fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C had a low risk of drug drug interactions, including with commonly used medications such as omeprazole and rosuvastatin.Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Summary Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR’s BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR’s $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie. Failure in both Phase 3 studies threatens AVIR’s survival, while success could trigger a share price spike or potential acquisition interest. Read the full article on Seeking AlphaHepatitis C Trial And Pricing Risks Will Dominate Outlook Yet Longer Term Potential Remains
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral antiviral therapies for hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Hepatitis Antiviral Pipeline Will Create Long Term Upside Potential
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral direct acting antiviral therapies for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Hepatitis C And E Antiviral Pipeline Will Reshape Long Term Outlook
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biotechnology company focused on developing oral direct acting antivirals for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Atea wins FDA Fast Track status for dengue treatment
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), a biotech focused on developing treatments for viral infections, announced Monday that the FDA granted Fast Track Designation to AT-752, an investigational oral therapy for dengue virus infection. Dengue is the most common mosquito-borne virus in the world, affecting an estimated up to 400M people annually. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. Developed using AVIR’s purine nucleotide prodrug platform, AT-752 is currently undergoing two proof-of-concept studies for dengue, with data expected at the end of the year. Read more on upcoming milestones for AVIR as outlined by the management in August.Atea Pharmaceuticals Q2 2022 Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.49 (-2550.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward.Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 16x, you may...Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Today is shaping up negative for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) shareholders, with the analysts delivering...Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
The latest analyst coverage could presage a bad day for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ), with the analysts...A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Atea Pharmaceuticals posted underwhelming data from a Phase 2 trial of its COVID antiviral therapy AT-527 on Oct. 19, causing its stock price to fall by 66%. The drug failed to meet its endpoint of reduction of the SARS-Cov-2 virus compared to placebo in a subset of patients - around two-thirds of whom were low risk. Atea has a similar mechanism of action to Merck's Molnupiravir, which looks likely to win Emergency Approval for mild-to-moderate COVID-19 patients who are at risk for progressing to severe COVID. If Atea management has used only unvaccinated patients with a serious underlying health issue, as Merck did, the outcome of its MOONSONG trial may have been different. As such, Atea may be able to alter pivotal trial protocols and still make it to market - although yesterday's data means that will not happen for at least another year, by which time, it may be too late.Rendement pour les actionnaires
| AVIR | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | 0.2% | -2.0% | 0.7% |
| 1Y | 36.0% | 44.4% | 20.6% |
Rendement vs Industrie: AVIR a sous-performé le secteur US Pharmaceuticals qui a rapporté 44.4 % au cours de l'année écoulée.
Rendement vs marché: AVIR a dépassé le marché US qui a rapporté 20.6 % au cours de l'année écoulée.
Volatilité des prix
| AVIR volatility | |
|---|---|
| AVIR Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: AVIR n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de AVIR ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2012 | 55 | Jean-Pierre Sommadossi | ateapharma.com |
Atea Pharmaceuticals, Inc. est une société biopharmaceutique en phase clinique qui découvre, développe et commercialise des thérapies antivirales orales pour les patients souffrant d'infections virales graves. Son principal produit candidat est le régime de bemnifosbuvir, un inhibiteur nucléotidique de la NS5B, et de ruzasvir, un inhibiteur de la NS5A, qui est en essai clinique de phase 3 pour le traitement du virus de l'hépatite C (VHC). L'entreprise développe également l'AT-587, qui est en essai clinique de phase 1 pour le traitement de l'infection chronique par le VHE.
Atea Pharmaceuticals, Inc. Résumé des fondamentaux
| AVIR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$392.93m |
| Bénéfices(TTM) | -US$169.52m |
| Recettes(TTM) | n/a |
Le site AVIR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| AVIR compte de résultat (TTM) | |
|---|---|
| Recettes | US$0 |
| Coût des recettes | US$159.32m |
| Marge brute | -US$159.32m |
| Autres dépenses | US$10.20m |
| Les revenus | -US$169.52m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -2.12 |
| Marge brute | 0.00% |
| Marge bénéficiaire nette | 0.00% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de AVIR?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/10 23:36 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Atea Pharmaceuticals, Inc. est couverte par 4 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Eric Joseph | J.P. Morgan |
| Matthew Harrison | Morgan Stanley |
| Maxwell Skor | Morgan Stanley |